[{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Secura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Secura Bio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical | Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG | Decipher Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bicalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG | Decipher Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG | Decipher Biosciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Medivation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Medivation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Medivation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Medivation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Medivation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Medivation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Medivation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Medivation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Medivation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AMG386","moa":"Angiopoietin-1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ BeOne Medicines"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Servier"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Leadiant Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Leadiant Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Leadiant Biosciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dana-Farber Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Comprehensive Cancer Network | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Institutes of Health | Candel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"rQNestin34.5v.2","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ National Institutes of Health | Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ National Institutes of Health | Candel Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"TG Therapeutics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Umbralisib Tosylate","moa":"Casein kinase I epsilon | PI3-kinase p110-delta subunit | Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ TG Therapeutics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ TG Therapeutics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BHV-1100","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MCS110","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ulocuplumab","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ulocuplumab","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Autologous Cytokine Induced Memory-Like NK Cell","moa":"||Cyclic ADP-ribose hydrolase 1 (CD38)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BAY1000394","moa":"Cyclin-dependent kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly | Effector Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly | Effector Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly | Effector Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ HiberCell","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ HiberCell"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Myriad genetics | Translational Breast Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Myriad genetics | Translational Breast Cancer Research Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Myriad genetics | Translational Breast Cancer Research Consortium"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca | Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sapacitabine","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca | Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca | Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Stemline Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"DNA | Glutamate carboxypeptidase II","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kite Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Kite Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Effector Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Astellas Pharma | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Crizotinib","moa":"EML4-ALK | Hepatocyte growth factor receptor | ALK tyrosine kinase receptor | NPM\/ALK (Nucleophosmin\/ALK tyrosine kinase receptor)","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Astellas Pharma | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Astellas Pharma | Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Erlotinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Translational Breast Cancer Research Consortium | Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CAS 698387-09-6","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2 | Receptor protein-tyrosine kinase erbB-4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Puma Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Puma Biotechnology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"William Lawrence and Blanche Hughes Foundation | Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ William Lawrence and Blanche Hughes Foundation | Karyopharm Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ William Lawrence and Blanche Hughes Foundation | Karyopharm Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Allergan"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rogaratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"EpicentRx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | Eisai Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | Eisai Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Prostate Cancer Foundation | Pfizer Inc | Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Prostate Cancer Foundation | Pfizer Inc | Myovant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Prostate Cancer Foundation | Pfizer Inc | Myovant Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Gonadorelin","moa":"Gonadotropin-releasing hormone receptor; Putative gonadotropin-releasing hormone II receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Partner Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Partner Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Partner Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Brigham and Women's Hospital | Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Brigham and Women's Hospital | Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Brigham and Women's Hospital | Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Merestinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Curis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fimepinostat","moa":"Histone deacetylase | PI3-kinase p110-beta subunit | PI3-kinase p110-alpha subunit | PI3-kinase p110-delta subunit||PI3-kinase p110-beta subunit | PI3-kinase p110-alpha subunit | Histone deacetylase | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Curis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Acetylon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Acetylon Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Acetylon Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Biogen"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | PROMETHEUS LABS"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Massachusetts General Hospital | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Massachusetts General Hospital | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Massachusetts General Hospital | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Beth Israel Deaconess Medical Center | Brigham and Women's Hospital | GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Brigham and Women's Hospital | GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Brigham and Women's Hospital | GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BioMed Valley Discoveries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ BioMed Valley Discoveries","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ BioMed Valley Discoveries"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LY3214996","moa":"Mitogen-activated protein kinase; ERK1\/ERK2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"LY3300054","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"NH TherAguix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gadolinium-Based Nanoparticle","moa":"MRI contrast","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ NH TherAguix","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ NH TherAguix"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genus Oncology, LLC | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GO-203-2c","moa":"Mucin-1 (MUC1)","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genus Oncology, LLC | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Genus Oncology, LLC | National Institutes of Health"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"The Ben & Catherine Ivy Foundation | Accelerate Brain Cancer Cure | Merck & Co | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Personalized Neoantigen Peptides","moa":"Neoantigen-targeting T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ The Ben & Catherine Ivy Foundation | Accelerate Brain Cancer Cure | Merck & Co | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ The Ben & Catherine Ivy Foundation | Accelerate Brain Cancer Cure | Merck & Co | National Institutes of Health"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BrainStorm Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ ImmunityBio","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ ImmunityBio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kidney Cancer Association","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Kidney Cancer Association","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Kidney Cancer Association"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Beth Israel Deaconess Medical Center | Akorn Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Akorn Inc","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Akorn Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"TeamConnor Childhood Cancer Foundation | Cookies for Kids' Cancer | Aileron Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ALRN-6924","moa":"p53-binding protein Mdm4 (MDM4)","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ TeamConnor Childhood Cancer Foundation | Cookies for Kids' Cancer | Aileron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ TeamConnor Childhood Cancer Foundation | Cookies for Kids' Cancer | Aileron Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Osteosarcoma Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Osteosarcoma Institute | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Osteosarcoma Institute | AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Immunogen | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Immunogen | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Immunogen | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co | Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co | Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech | Stand Up To Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech | Stand Up To Cancer","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech | Stand Up To Cancer"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ EMD Serono","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ EMD Serono"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"LY3022855","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Buparlisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Buparlisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Secura Bio","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Secura Bio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Secura Bio","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Secura Bio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG | Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Tesaro","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Tesaro","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Tesaro"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Translational Breast Cancer Research Consortium | Johns Hopkins University | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Johns Hopkins University | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Johns Hopkins University | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Epizyme | Pfizer Inc | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Talazoparib","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Epizyme | Pfizer Inc | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Epizyme | Pfizer Inc | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Talazoparib","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio | Bristol Myers Squibb | Miltenyi Biomedicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"N-803","moa":"receptor molecules","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ ImmunityBio | Bristol Myers Squibb | Miltenyi Biomedicine","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ ImmunityBio | Bristol Myers Squibb | Miltenyi Biomedicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc | Breast Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ARRY-380","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc | Breast Cancer Research Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc | Breast Cancer Research Foundation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eisai Inc | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eisai Inc | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eisai Inc | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Kadcyla","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Kadcyla","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Kadcyla","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Puma Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Puma Biotechnology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Memorial Sloan Kettering Cancer Center | University of California, Los Angeles | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"MK2206","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Memorial Sloan Kettering Cancer Center | University of California, Los Angeles | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Memorial Sloan Kettering Cancer Center | University of California, Los Angeles | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Prexasertib","moa":"Serine\/threonine-protein kinase Chk2 | Serine\/threonine-protein kinase Chk1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adavosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Bristol Myers Squibb | Blood Cancer Research Partnership | Multiple Myeloma Research Consortium | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Bristol Myers Squibb | Blood Cancer Research Partnership | Multiple Myeloma Research Consortium | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Bristol Myers Squibb | Blood Cancer Research Partnership | Multiple Myeloma Research Consortium | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Regeneron Pharmaceuticals | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PTZ-201","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals | Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals | Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Paxman Coolers | AstraZeneca | Eisai Inc | Daiichi Sankyo | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Paxman Coolers | AstraZeneca | Eisai Inc | Daiichi Sankyo | Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Paxman Coolers | AstraZeneca | Eisai Inc | Daiichi Sankyo | Gilead Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eisai Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eisai Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"MacroGenics | Translational Breast Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ MacroGenics | Translational Breast Cancer Research Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ MacroGenics | Translational Breast Cancer Research Consortium"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Invios","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pharmacyclics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pharmacyclics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pharmacyclics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pharmacyclics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Pharmacyclics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CDX-301","moa":"Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Celldex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"223-Ra","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"NH TherAguix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Aguix","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ NH TherAguix","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ NH TherAguix"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cytokine Induced Memory-Like Natural Killer Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ensure","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Abbott Laboratories"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Entrinsic Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Enterade","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Entrinsic Health","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Entrinsic Health"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Oncovir | BioNTech | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Neoantigen-Based Personalized Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Oncovir | BioNTech | Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Oncovir | BioNTech | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Red Queen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"RQ-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SHIRE PLC | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SC-PEG","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ SHIRE PLC | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ SHIRE PLC | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"VBL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VB11","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ VBL Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ VBL Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Exelixis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Exelixis | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Exelixis | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Exelixis | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | Pharmavite","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | Pharmavite","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | Pharmavite"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research"}]
Find Clinical Drug Pipeline Developments & Deals by Dana-Farber Cancer Institute
Details :
177Lu-PSMA-617 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Details :
NeoVax is a combination of neoantigen peptides and poly-ICLC which is being evaluated in combination with ipilimumab for the treatment of renal cell carcinoma.
Product Name : NeoVax
Product Type : Vaccine
Upfront Cash : Inapplicable
February 06, 2025
Lead Product(s) :
Neoantigen-Based Personalized Vaccine,NEO-PV-01,Ipilimumab
Details :
Belzutifan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Details :
The collaboration aims to conduct an investigator-sponsored trial evaluating zotatifin in patients with estrogen receptor-positive endometrial cancer and low-grade serous ovarian cancer.
Details :
Abemaciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endometrial Neoplasms.
Details :
CIML NK Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.
Details :
CIML NK Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.
Details :
Carboplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Details :
The collaboration aims to evaluate invIOs’ small molecule INV501 that can selectively enhance anti-tumor immune responses, as a potential treatment for glioblastoma.